Sparsentan

CAS 254740-64-2 3 current recordsSmall Molecule

Who holds supplier records for Sparsentan? 3 organisations hold a current record for Sparsentan: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: India (3).

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Sparsentan: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/sparsentan

Reading the evidence

  • 3 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in India

    3 of the 3 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.

  • 2 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Sparsentan expires 13 Oct 2037. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (3)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Sparsentan. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Sparsentan sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (2 listed products contain Sparsentan). The latest listed patent expires 13 Oct 2037. The latest listed exclusivity runs to 5 Sept 2031. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Sparsentan is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL539423).

Chemical identity

IUPAC name
2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-N-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide
Canonical SMILES
CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC(=C(C=C3)C4=CC=CC=C4S(=O)(=O)NC5=NOC(=C5C)C)COCC
InChIKey
WRFHGDPIDHPWIQ-UHFFFAOYSA-N
Synonyms
Esparsentan, Filspari, PS-433540, PS433540, RE-021, Sparsentan, sparsentanum, RefChem:56752, Sparsentan (RE-021), Sparsentan [USAN], RE 201, retrophin

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Angiotensin 2 Receptor Blocker; Endothelin Receptor Antagonist
Mechanism of action
Angiotensin 2 Type 1 Receptor Antagonists; Breast Cancer Resistance Protein Inhibitors; Cytochrome P450 2B6 Inducers; Cytochrome P450 2C19 Inducers; Cytochrome P450 2C9 Inducers; Endothelin Receptor Antagonists; P-Glycoprotein Inhibitors

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Sparsentan?

3 organisations hold an active US FDA Type II Drug Master File or a CEP for Sparsentan: APITORIA PHARMA PRIVATE LTD (India), BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (India) and MSN LIFE SCIENCES PRIVATE LIMITED (India). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Sparsentan Drug Master Files are active?

APITORIA PHARMA PRIVATE LTD (DMF 44533), BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (DMF 44720) and MSN LIFE SCIENCES PRIVATE LIMITED (DMF 41498). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

Does the FDA Orange Book list patents for products containing Sparsentan?

Yes. The latest patent listed for an approved US product containing Sparsentan expires 13 Oct 2037, across 2 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Sparsentan supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Sparsentan?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.